Wistar and Accelerated Biosciences Partner to Develop Novel hTSCs Platform for Immunotherapies

On July 10, The Wistar Institute (Wistar) and Accelerated Biosciences Corp. formally announced their collaboration that will focus on developing an innovative platform utilizing human trophoblast stem cells (hTSCs). This research partnership will explore new immunotherapies leveraging Accelerated Bio’s proprietary technology, holding the potential to revolutionize the field of allogeneic immunotherapies through the generation of immune cells from hTSCs.

Accelerated Bio’s Ethically Sourced hTSC Platform to Accelerate Immunotherapy Research

Accelerated Bio’s hTSC platform will be responsible for driving the collaboration. These hTSCs possess high plasticity and immune privilege, enabling them to evade detection and attack by the immune system. This characteristic makes them an ideal strategy for a wide range of medical and biotechnological applications, including therapy development, drug discovery, biomanufacturing, and toxicology testing. Additionally, Accelerated Bio ethically sources hTSC from pre-implementation and early-stage pluripotent stem cells.

Herbert Kean, Vice President of Scientific Operations at the Wistar Institute, and Luis J. Montaner, a prominent scientist with a veterinary and doctoral degree, expressed their enthusiasm for the collaboration with Accelerated Bio. They stated that this partnership aligned perfectly with Wistar’s goals to develop innovative immunotherapy strategies rooted in a deep understanding of the human immune system. They expressed excitement about exploring Accelerated Bio’s hTSCs, emphasizing their potential to create superior allogeneic cell therapies for diseases such as HIV and cancer.

Furthermore, the capabilities of the hTSC platform and its untapped potential were emphasized by Accelerated Bio’s CEO, Yuta Lee, “Our hTSC platform is not only the earliest ethically sourced pluripotent stem cell source available but also one of the most dynamic and versatile. This research collaboration with Wistar will enhance our understanding of hTSCs and demonstrate their potential to revolutionize the cell therapy industry.”

Through their collaboration, Wistar and Accelerated Biosciences seek to innovate the production of engineered allogeneic immune cells for immunotherapy. Furthermore, their objective is to simplify manufacturing, reduce costs, and also minimize therapeutic risks, thereby enhancing the efficiency of this treatment.

Author

Denisse Sandoval